PBAC's latest decision on Travoprost with timolol maleate, eye drops: Recommended with restriction (2007). Considered for Reduction of elevated intra-ocular pressure in patients with open angle glaucoma or ocular hypertension, who are not adequately controlled with beta-blockers or prostaglandin analogues.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2006
Submissions
2
2006 → 2007
Eligible population
patients with open angle glaucoma or ocular hypertension, who are not adequately controlled with beta-blockers or prostaglandin analogues
Therapy area
Ophthalmology
Line of therapy
Later-line
Evidence base
RCT
Key trials
not stated
Comparator
concomitant administration of latanoprost and timolol
Economic model
Cost-minimisation
ICER note
Cost minimisation basis; no economic evaluation presented
Submission history
Jul 2006: Recommended with restriction · Restricted
Mar 2007: Recommended with restriction · Restricted